Inhibition of angiogenic activity of renal carcinoma by an antisense oligonucleotide targeting fibroblast growth

Related Experiment Video

Updated: Jun 18, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Elisabetta Cenni1, Francesca Perut, Monia Zuntini

  • 1Laboratory for Pathophysiology of Orthopedic Implants, Istituti Ortopedici Rizzoli, Bologna, Italy. elisabetta.cenni@ior.it

Anticancer Research
|May 5, 2005
PubMed
Abstract

Insights

Antisense phosphorothioate oligodeoxynucleotide (PS-ODN2) targeting fibroblast growth factor-2 (FGF-2) minimally affected FGF-2 expression in renal carcinoma cells. However, PS-ODN2 significantly inhibited endothelial cell migration, suggesting a potential therapeutic avenue.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Fibroblast growth factor-2 (FGF-2) is a key inducer of angiogenesis.
  • Angiogenesis is essential for tumor growth and metastasis.

Purpose of the Study:

  • To evaluate the effect of blocking FGF-2 synthesis on the angiogenic activity of renal carcinoma cell lines.
  • To assess the efficacy of antisense phosphorothioate oligodeoxynucleotide (PS-ODN2) in inhibiting FGF-2 production and its downstream effects.

Main Methods:

  • Transfection of Caki-1 and CRBM-1990 cell lines with PS-ODN2.
  • Evaluation of FGF-2 mRNA and protein expression post-transfection.
  • Assessment of angiogenic activity, including endothelial cell migration, using conditioned media.

Main Results:

  • PS-ODN2 treatment resulted in non-significant decreases in FGF-2 expression in both cell lines.
  • Conditioned media from PS-ODN2-treated Caki-1 cells significantly reduced endothelial cell migration.
  • PS-ODN2 treatment decreased intracellular FGF-2 protein in CRBM-1990 cells but did not impair their ability to induce endothelial cell migration and proliferation.

Conclusions:

  • PS-ODN2 demonstrated minimal impact on FGF-2 expression in established renal carcinoma cell lines.
  • Despite minimal changes in FGF-2 levels, PS-ODN2 inhibited endothelial cell migration, indicating a potential anti-angiogenic effect.
  • The study suggests a complex interplay between FGF-2 expression and angiogenic potential in renal carcinoma.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...